The combination of pan-EGFR inhibitor neratinib was synergistic with niraparib in ovarian cancer cell lines as well, leading to the ongoing clinical trial evaluating the combination in patients with platinum-resistant, BRCA1/2 wild-type ovarian cancer (NCT04502602) [75]. Here, BRCA1 is linked to ovarian cancer.